Jane Street Group LLC Sells 56,878 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Jane Street Group LLC cut its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 70.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,613 shares of the biopharmaceutical company's stock after selling 56,878 shares during the period. Jane Street Group LLC's holdings in Vanda Pharmaceuticals were worth $113,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of VNDA. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth approximately $1,296,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth approximately $1,221,000. Dimensional Fund Advisors LP grew its position in shares of Vanda Pharmaceuticals by 10.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company's stock worth $11,920,000 after buying an additional 227,428 shares during the period. Monaco Asset Management SAM grew its position in shares of Vanda Pharmaceuticals by 92.8% during the 4th quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company's stock worth $1,879,000 after buying an additional 188,836 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Vanda Pharmaceuticals by 108.9% during the 4th quarter. JPMorgan Chase & Co. now owns 335,741 shares of the biopharmaceutical company's stock worth $1,608,000 after buying an additional 175,019 shares during the period. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Stock Down 1.7%

NASDAQ VNDA traded down $0.08 during trading on Wednesday, reaching $4.58. 296,187 shares of the stock traded hands, compared to its average volume of 658,290. The firm has a market cap of $269.92 million, a price-to-earnings ratio of -14.31 and a beta of 0.66. The stock's 50-day moving average price is $4.31 and its 200 day moving average price is $4.56. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.81 and a fifty-two week high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.05. The firm had revenue of $50.04 million during the quarter, compared to analysts' expectations of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. Analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on VNDA. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, May 7th. Cantor Fitzgerald restated an "overweight" rating and set a $13.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos acquired 20,000 shares of the business's stock in a transaction dated Friday, May 16th. The shares were acquired at an average price of $4.22 per share, with a total value of $84,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,315,731 shares in the company, valued at $9,772,384.82. This trade represents a 0.87% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 10.00% of the company's stock.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.